NDAOPHTHALMICIMPLANT
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
DURYSTA (bimatoprost) by AbbVie is bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. First approved in 2020.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURYSTA is a sustained-release bimatoprost implant (prostaglandin analog) administered as a single intracameral injection for glaucoma and ocular hypertension. It lowers intraocular pressure (IOP) by increasing aqueous humor outflow via trabecular meshwork and uveoscleral routes. The implant delivers consistent drug levels over an extended period, addressing a major risk factor for glaucomatous vision loss.
$0.965MPart D
Peak8.4 years to LOEProduct at peak lifecycle with modest Part D penetration suggests established market position; team likely focused on market consolidation and physician adoption in specialty ophthalmology.
Mechanism of Action
Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional).…
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
Started Feb 2023
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
Started Jun 2022
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Started Mar 2021
220 enrolled
Open-angle GlaucomaOcular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
Started Jun 2020
37 enrolled
Open-Angle GlaucomaOcular Hypertension
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Started Mar 2019
455 enrolled
Open-Angle GlaucomaOcular Hypertension
Worked on DURYSTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.